Navigation Links
University of Colorado and Orphan Technologies sign agreement
Date:2/22/2013

The University of Colorado (CU) has signed exclusive, worldwide licensing and collaboration agreements with rare-disease research-and-development firm Orphan Technologies Ltd to develop an enzyme replacement therapy for Cystathionine Beta-Synthase (CBS) -deficient homocystinuria, a rare, inherited metabolic disease that is often fatal at a young age. The collaboration was initiated in 2010 and includes sponsored-research funding by OT to continue development of the treatment approach pioneered by Jan P. Kraus, a professor of pediatrics at the CU School of Medicine. Orphan Technologies plans to begin first-in-human trials in 2014.

CBS-deficient homocystinuria is a rare genetic disorder caused by low levels of active CBS enzyme. Individuals with this disease are unable to fully metabolize the amino acid methionine, which is found in nearly all foods. That leads to the accumulation of toxic levels of related metabolites (molecules that are the product of metabolism), and deficits in others.

Patients with homocystinuria suffer major multi-systemic disorder, including mental retardation, dislocation of the lens of the eye (leading to blindness if not treated), seizures, osteoporosis and stroke. Taken together, these lead to a significantly shorter life expectancy; almost one fourth of untreated patients die before the age of 30.

About 40% of patients with homocystinuria benefit from vitamin B6 supplementation. But for the rest, treatment is limited to a methionine-restricted (low protein) diet and supplementation with cystine, folate, and betaine (Cystadane) which partially restore metabolic balance; however, these treatment approaches do not repair the broken methionine metabolic cycle and don't resolve all metabolic abnormalities, so patients still suffer from severe, life-threating symptoms.

Professor Kraus has devised an enzyme replacement therapy to correct the underlying cause of the disease. This approach has the potential to restore the norm
'/>"/>

Contact: Lindsey Lennox
lindsay.lennox@cu.edu
University of Colorado Denver
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Brown University researchers build robotic bat wing
2. Wayne State University researchers techniques enable more, faster testing of biological liquids
3. University of Arizona Engineering College pursues water technology innovation cluster
4. Brown University scientists to discuss resilience of coastal communities at AAAS
5. New Research Conducted by University Cancer Centers Links BP Refinery Incident to Increase Occurrence of Cancer in Texas City
6. University of Florida reports 2012 US shark attacks highest since 2000
7. Rice University lab show how blood vessels regroup after stroke
8. Sustaining Coastal Cities Conference at Northeastern University
9. In a fight to the finish, Saint Louis University research aims knockout punch at hepatitis B
10. University-developed omega-3-rich ground beef available soon
11. Aarhus University builds research station in North Greenland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics ... banking and upgradation of the driver,s license is ... market. Besides the aforementioned projects, biometrics is being ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... has been implicated in heart disease, weight gain, and diabetes, ... a source of chronic stress, present a challenge even for ... some species somehow manage to survive, and even thrive, in ... Yuri Springer in the November issue of the American ...
... Medical Center in New York have confirmed that Homo ... a descendant of healthy humans dwarfed by disease. Using ... researchers determined the "hobbit" to be a distinct species and ... of the study appear in the December issue of ...
... that can boost fuel efficiency without sacrificing safety and durability ... tires could help add an extra mile or two per ... the cover story of the current issue of Chemical & ... Editor Alexander Tullo explains that rolling resistance the friction ...
Cached Biology News:The benefits of stress ... in plants 2'Hobbits' are a new human species -- according to the statistical analysis of fossils 2
(Date:12/17/2014)... Texas , Dec. 16, 2014  Vermillion, Inc. ... focused on gynecologic disease, today announced the next step ... a premier bio-analytics solutions provider with the naming of ... President and Chief Executive Officer, while current Chairman of ... continue to serve as Chairman. These changes are effective ...
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
(Date:12/15/2014)... PETACH TIKVAH, Israel , Dec. 15, ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd. was awarded a grant of ... Office of the Chief Scientist (OCS).  This is the ... grant support from the Office of the Chief Scientist, ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... Satisfies initial listing requirements with NASDAQ; Stock ... which extends cash runway while focusing ... Aug. 21 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals, Inc. (formerly ... "Company") announced that the Company has completed ...
... Management and Supports Best-Of-Breed, Clinical Environments - Without ... ... Software Upgrades, OAKLAND, Calif., Aug. 21 ... and information,systems, and Epiphany Cardiography Products, introduce CardioECG 3.2,multi-modality, multi-vendor, ...
... Netherlands, August 21 Hoya,Corporation,s Vision Care Division, a ... today that it acquired Dioptra CZ a.s., one of,the ... Dioptra has a long and rich tradition in ... and Dioptra have worked together under an,exclusive arrangement since ...
Cached Biology Technology:Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 2Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 3Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 4Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 5Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 6LUMEDX Introduces Advanced Multi-Modality, Multi-Vendor, Web-Enabled ECG Management Solution 2Hoya Vision Care Expands in Czech Republic 2